Vanguard Group
SABS icon

Vanguard Group’s SAB Biotherapeutics SABS Stock Holding History

Vanguard Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.91M Buy
1,847,136
+1,481,383
+405% +$4.87M ﹤0.01% 3132
2025
Q3 		$735K Buy
365,753
+83,382
+30% +$189K ﹤0.01% 3864
2025
Q2 		$494K Buy
282,371
+4,861
+2% +$8.04K ﹤0.01% 3920
2025
Q1 		$375K Buy
277,510
+135
+0% +$310 ﹤0.01% 3945
2024
Q4 		$1.06M Buy
277,375
+1,039
+0.4% +$3.41K ﹤0.01% 3747
2024
Q3 		$746K Hold
276,336
– – ﹤0.01% 3859
2024
Q2 		$857K Buy
276,336
+100,002
+57% +$367K ﹤0.01% 3851
2024
Q1 		$801K Buy
176,334
+76,721
+77% +$422K ﹤0.01% 3883
2023
Q4 		$685K Buy
99,613
+1,919
+2% +$16.1K ﹤0.01% 3941
2023
Q3 		$615K Buy
97,694
+1,420
+1% +$10.4K ﹤0.01% 3995
2023
Q2 		$799K Buy
96,274
+26,116
+37% +$214K ﹤0.01% 3968
2023
Q1 		$309K Hold
70,158
– – ﹤0.01% 4241
2022
Q4 		$414K Buy
70,158
+58
+0.1% +$530 ﹤0.01% 4153
2022
Q3 		$491K Sell
70,100
-2,065
-3% -$20.5K ﹤0.01% 4211
2022
Q2 		$1.05M Buy
72,165
+50
+0.1% +$1.05K ﹤0.01% 4072
2022
Q1 		$2.71M Buy
72,115
+3,818
+6% +$176K ﹤0.01% 3823
2021
Q4 		$5.33M Buy
+68,297
New +$6.41M ﹤0.01% 3568

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Vanguard Group's SABS Position: Q4 2025 in Review

Vanguard Group increased its SAB Biotherapeutics (SABS) stake by 405% in Q4 2025, buying an estimated $4.87M and bringing the position to 1,847,136 shares worth $6.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3132.

Vanguard Group first reported a position in SABS in Q4 2021 and has held it in 17 quarters since. 48 funds tracked by Wall St. Rank hold SABS as of Q4 2025.

  • Vanguard Group held 1,847,136 shares of SAB Biotherapeutics worth $6.91M as of Q4 2025.
  • Vanguard Group bought 1,481,383 SAB Biotherapeutics shares in Q4 2025, an estimated $4.87M.
  • SAB Biotherapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3132 holding.
  • Vanguard Group first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 17 quarters since.
  • 48 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.